The objective of the current research was to explore the potential prognostic value of readily available clinical and pathologic variables in bladder cancer. The novel association found between cholesterol levels and prognosis may provide the rationale for exploring novel treatments. Patients included had histologically confirmed urothelial bladder cancer and were treated with at least 3 cycles of cisplatin-based neoadjuvant chemotherapy before radical cystectomy with lymphadenectomy. A total of 245 patients at low, intermediate and high risk, presenting with 0-1, 2 or 3-4 risk factors, including positive lymph nodes, Hb <12.8, NLR ≥2.7 and cholesterol levels ≥199, were included. Five-year cancer-specific survival rate was 0.67, 0.78 and 0.94 at high, intermediate and low risk, respectively. Total cholesterol levels at the time of cystectomy may represent a commonly assessable prognostic factor and may be incorporated in a clinically meaningful risk-group classification model.
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy / Ferro, Matteo; Lucarelli, Giuseppe; de Cobelli, Ottavio; Dolce, Pasquale; Terracciano, Daniela; Musi, Gennaro; Porreca, Angelo; Busetto, Gian Maria; Del Giudice, Francesco; Soria, Francesco; Gontero, Paolo; Cantiello, Francesco; Damiano, Rocco; Crocerossa, Fabio; Abu Farhan, Abdal Rahman; Autorino, Riccardo; Vartolomei, Mihai Dorin; Marchioni, Michele; Mari, Andrea; Minervini, Andrea; Longo, Nicola; Celentano, Giuseppe; Chiancone, Francesco; Perdonà, Sisto; Del Prete, Paola; Ditonno, Pasquale; Battaglia, Michele; Zamboni, Stefania; Antonelli, Alessandro; Greco, Francesco; Russo, Giorgio Ivan; Hurle, Rodolfo; Crisan, Nicolae; Manfredi, Matteo; Porpiglia, Francesco; Ribera, Dario; De Placido, Pietro; Facchini, Sergio; Scafuri, Luca; Verde, Antonio; Di Lorenzo, Giuseppe; Cosimato, Vincenzo; Luciano, Angelo; Caputo, Vincenzo Francesco; Crocetto, Felice; Buonerba, Carlo. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - (2021). [10.2217/fon-2020-1298]
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy
Ferro, Matteo;Lucarelli, Giuseppe;Dolce, Pasquale;Terracciano, Daniela;Musi, Gennaro;Longo, Nicola;Chiancone, Francesco;Ribera, Dario;De Placido, Pietro;Scafuri, Luca;Cosimato, Vincenzo;Caputo, Vincenzo Francesco;Crocetto, Felice;Buonerba, Carlo
2021
Abstract
The objective of the current research was to explore the potential prognostic value of readily available clinical and pathologic variables in bladder cancer. The novel association found between cholesterol levels and prognosis may provide the rationale for exploring novel treatments. Patients included had histologically confirmed urothelial bladder cancer and were treated with at least 3 cycles of cisplatin-based neoadjuvant chemotherapy before radical cystectomy with lymphadenectomy. A total of 245 patients at low, intermediate and high risk, presenting with 0-1, 2 or 3-4 risk factors, including positive lymph nodes, Hb <12.8, NLR ≥2.7 and cholesterol levels ≥199, were included. Five-year cancer-specific survival rate was 0.67, 0.78 and 0.94 at high, intermediate and low risk, respectively. Total cholesterol levels at the time of cystectomy may represent a commonly assessable prognostic factor and may be incorporated in a clinically meaningful risk-group classification model.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
